Tariff shock: 100% levy on branded/patented drug imports unless firms are actively building U.S. plants (effective 1 Oct 2025). Generics are excluded. Exemption applies if construction has started (“breaking ground” / “under construction”).

Winners — U.S. Manufacturing & Infrastructure

Reason: A rush to onshore capacity should boost companies that build, equip, and service pharma plants in the U.S. as drugmakers seek tariff exemptions.

Equipment & tools: $TMO (Thermo Fisher Scientific), $DHR (Danaher)

Engineering & build-out: $FLR (Fluor), $J (Jacobs)

Winners — U.S.-based Big Pharma with deep domestic footprints

Reason: Imported rivals face a 100% tariff, tilting pricing power and formulary leverage toward U.S.-made brands and encouraging more domestic production.

Innovators:  ...